Combined Inhibition of STAT3 and DNA Repair in Palbociclib-Resistant ER-Positive Breast Cancer.

Kettner, Nicole; Vijayaraghavan, Smruthi; Durak, MERİH; Bui, Tuyen; Kohansal, Mehrnoosh; Ha, Min; Liu, Bin; Rao, Xiayu; Wang, Jing; Yi, Min; Carey, Jason; Chen, Xian; Eckols, T.; Raghavendra, Akshara; Ibrahim, Nuhad; Karuturi, Meghan; Watowich, Stephanie; Sahin, Aysegul; Tweardy, David; Hunt, Kelly; Tripathy, Debu; Keyomarsi, Khandan

doi:10.1158/1078-0432.ccr-18-3274

Combined Inhibition of STAT3 and DNA Repair in Palbociclib-Resistant ER-Positive Breast Cancer.

Kettner N. M., Vijayaraghavan S., Durak M., Bui T., Kohansal M., Ha M. J., ...Daha Fazla

Clinical cancer research : an official journal of the American Association for Cancer Research, cilt.25, sa.13, ss.3996-4013, 2019 (SCI-Expanded, Scopus)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 25 Sayı: 13
Basım Tarihi: 2019
Doi Numarası: 10.1158/1078-0432.ccr-18-3274
Dergi Adı: Clinical cancer research : an official journal of the American Association for Cancer Research
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Sayfa Sayıları: ss.3996-4013
Açık Arşiv Koleksiyonu: AVESİS Açık Erişim Koleksiyonu
Dokuz Eylül Üniversitesi Adresli: Evet

Özet

Purpose: Cyclin-dependent kinase 4/6 (CDK4/6) inhibitors are currently used in combination with endocrine therapy to treat advanced hormone receptor-positive, HER2-negative breast cancer. Although this treatment doubles time to progression compared with endocrine therapy alone, about 25%-35% of patients do not respond, and almost all patients eventually acquire resistance. Discerning the mechanisms of resistance to CDK4/6 inhibition is crucial in devising alternative treatment strategies.